IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

IFN-γ-driven inflammation causes long-term bone marrow niche dysfunction after doxorubicin chemotherapy, impairing hematopoietic and skeletal health.

• Why it matters: Understanding the mechanisms behind chemotherapy-induced bone marrow damage is crucial to improve survivorship and quality of life for cancer patients, as current knowledge is limited.
• What they did: Using a mouse model of doxorubicin-based leukemia therapy, the study examined inflammatory changes, vascular loss, and MSC differentiation blockade, alongside analysis of patient bone marrow samples, focusing on IFN-γ signaling.
• The result: Blocking IFN-γ signaling partially restored vascular and MSC function, and combined therapy with vascular-promoting agents reduced skeletal damage, highlighting inflammatory pathways as therapeutic targets.